Pure Global

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors - Trial NCT05774873

Access comprehensive clinical trial information for NCT05774873 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 128 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05774873
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05774873
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
A Phase 1 Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Study Focus

Solid Tumors

IBI334

Interventional

drug

Sponsor & Location

Innovent Biologics (Suzhou) Co. Ltd.

Waratah, Australia

Timeline & Enrollment

Phase 1

Jul 31, 2023

Jun 30, 2026

128 participants

Primary Outcome

Number of patients with treatment-related adverse events,Percentage of subjects woth Dose-Limitine toxicities(DLTs)

Summary

The primary objective of this study to evaluate the safety and tolerability of IBI334 and
 determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI334.

ICD-10 Classifications

Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm of other connective and soft tissue
Carcinoma in situ, unspecified
Malignant neoplasms
Malignant neoplasm: Parametrium

Data Source

ClinicalTrials.gov

NCT05774873

Non-Device Trial